> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Clears Vertex IND for Diabetes Therapy
- URL: https://www.fdaweb.com/fda-clears-vertex-ind-for-diabetes-therapy/
- Published: 2021-01-29T12:00:00.000Z
- Updated: 2026-09-14T16:44:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148559

FDA has cleared a Vertex Pharmaceuticals IND to proceed with a clinical trial for VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell therapy to treat Type 1 diabetes. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including insulin production, the company says.

Vertex plans to initiate a Phase 1/2 clinical trial in the first half this year in patients who have Type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. “This will be a sequential, multi-part clinical trial to evaluate the safety and efficacy of different doses of VX-880,” it says, adding that about 17 patients will be enrolled in the clinical trial.